Sickle Cell Disease Trial, Recruiting NCT04416178 Sponsor: St. Jude Children's Research Hospital Condition: Sickle Cell Disease
Back to Sickle Cell Disease

Sickle Cell Disease Trial, Recruiting

NCT04416178
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Group 1 – Survey and Interview:

  • Parents of a child (aged 12 months to 18 years) who has been diagnosed with a specific type of sickle cell disease (HbSS, HbS/β0 thalassemia, or HbSC), regardless of how severe the condition is, or patients aged 13–18 with one of these diagnoses
  • Participants who have previously been approached about a study called SCRIPP
  • Written agreement to take part must be provided by a parent or legal guardian, and teenagers must also give their own agreement

Group 2 – Focus Group:

  • Adult patients with, or parents of a child (aged 12 months to 18 years) with, a specific type of sickle cell disease (HbSS, HbS/β0 thalassemia, β+ thalassemia, or HbSC), regardless of how severe the condition is, or patients aged 16–18 with one of these diagnoses
  • Written agreement to take part must be provided by a parent or legal guardian, and teenagers must also give their own agreement

Group 3 – Usability and Pilot Testing:

  • Parents of a child (aged 12 months to 18 years) with a specific type of sickle cell disease (HbSS, HbS/β0 thalassemia, β+ thalassemia, or HbSC), regardless of how severe the condition is, or patients aged 13 and older with one of these diagnoses
  • Written agreement to take part must be provided by a parent or legal guardian, and teenagers must also give their own agreement

Who may not be able to join:

  • People who are not able to hold a fluent conversation in English
  • People whose overall health condition or a long-term illness makes participation unsafe or not practical — for example, a significant cognitive impairment or a serious illness happening at the same time (the trial team may reassess this at a later point)
  • People who are unwilling or unable to provide written consent to participate, and cases where a parent or legal guardian is unwilling or unable to provide that consent on behalf of a child

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Liza M. Johnson, MD, MPH, MSB, St. Jude Children's Research Hospital

Phone: 888-226-4343

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
St. Jude Children's Research Hospital
Registry
ClinicalTrials.gov
Start date
17 December 2020
Est. completion
26 March 2024

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Use of semi-structured interviews in parents of SCD patients to qualitatively describe parental attitudes of research involving genomic sequencing, including concerns about participation and expectations from researchers; Use of surveys to quantitatively measure genetic/genomic knowledge, trust in health care provider/researchers, and literacy/numeracy ability in parents of children with SCD and adolescents with SCD.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov